Protalix BioTherapeutics (NYSE:PLX) Stock Rating Upgraded by StockNews.com

Protalix BioTherapeutics (NYSE:PLX) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.

Protalix BioTherapeutics Price Performance

PLX opened at $1.80 on Thursday. The stock’s 50 day simple moving average is $1.35 and its 200 day simple moving average is $1.18. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $1.90. The firm has a market cap of $132.53 million, a price-to-earnings ratio of -13.85 and a beta of 0.74.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP grew its holdings in shares of Protalix BioTherapeutics by 8.5% in the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after acquiring an additional 33,969 shares during the period. Squarepoint Ops LLC lifted its position in shares of Protalix BioTherapeutics by 673.3% in the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after acquiring an additional 119,949 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Protalix BioTherapeutics in the second quarter valued at about $80,000. Ground Swell Capital LLC purchased a new position in shares of Protalix BioTherapeutics in the second quarter valued at about $73,000. Finally, AQR Capital Management LLC purchased a new position in shares of Protalix BioTherapeutics in the second quarter valued at about $67,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.